Literature DB >> 26703964

Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study.

Massimo Federico1, Stefano Luminari2, Cinzia Pellegrini3, Francesco Merli4, Emanuela Anna Pesce2, Stephane Chauvie5, Letizia Gandolfi3, Isabella Capodanno4, Massimiliano Salati2, Lisa Argnani3, Pier Luigi Zinzani3.   

Abstract

Entities:  

Keywords:  ABVD; Hodgkin lymphoma; brentuximab vedotin; early; intermediate; radiotherapy; toxicity

Mesh：

Substances：

Year:  2015        PMID： 26703964      PMCID： PMC5004404          DOI： 10.3324/haematol.2015.138388

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

Review 1.  Late effects in the era of modern therapy for Hodgkin lymphoma.

Authors:  David C Hodgson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.

Authors:  Ajay K Gopal; Robert Chen; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Joseph M Connors; Andreas Engert; Emily K Larsen; Xuedong Chi; Eric L Sievers; Anas Younes
Journal:  Blood       Date:  2014-12-22       Impact factor: 22.113

3.  Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

Authors:  John M M Raemaekers; Marc P E André; Massimo Federico; Theodore Girinsky; Reman Oumedaly; Ercole Brusamolino; Pauline Brice; Christophe Fermé; Richard van der Maazen; Manuel Gotti; Reda Bouabdallah; Catherine J Sebban; Yolande Lievens; Allessandro Re; Aspasia Stamatoullas; Frank Morschhauser; Pieternella J Lugtenburg; Elisabetta Abruzzese; Pierre Olivier; Rene-Olivier Casasnovas; Gustaaf van Imhoff; Tiana Raveloarivahy; Monica Bellei; Thierry van der Borght; Stephane Bardet; Annibale Versari; Martin Hutchings; Michel Meignan; Catherine Fortpied
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

4.  Treatment of Hodgkin lymphoma: a 50-year perspective.

Authors:  George P Canellos; Saul A Rosenberg; Jonathan W Friedberg; T Andrew Lister; Vincent T Devita
Journal:  J Clin Oncol       Date:  2014-01-20       Impact factor: 44.544

5.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Authors:  Anas Younes; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Radhakrishnan Ramchandren; Nancy L Bartlett; Bruce D Cheson; Sven de Vos; Andres Forero-Torres; Craig H Moskowitz; Joseph M Connors; Andreas Engert; Emily K Larsen; Dana A Kennedy; Eric L Sievers; Robert Chen
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

6.  Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

Authors:  Anas Younes; Joseph M Connors; Steven I Park; Michelle Fanale; Megan M O'Meara; Naomi N Hunder; Dirk Huebner; Stephen M Ansell
Journal:  Lancet Oncol       Date:  2013-11-15       Impact factor: 41.316

7.  Long-term cause-specific mortality of patients treated for Hodgkin's disease.

Authors:  Berthe M P Aleman; Alexandra W van den Belt-Dusebout; Willem J Klokman; Mars B Van't Veer; Harry Bartelink; Flora E van Leeuwen
Journal:  J Clin Oncol       Date:  2003-07-28       Impact factor: 44.544

8.  Risk of multiple primary malignancies following treatment of Hodgkin lymphoma.

Authors:  Anna M van Eggermond; Michael Schaapveld; Pieternella J Lugtenburg; Augustinus D G Krol; Jan Paul de Boer; Josée M Zijlstra; John M M Raemaekers; Leontien C M Kremer; Judith M Roesink; Marieke W J Louwman; Berthe M P Aleman; Flora E van Leeuwen
Journal:  Blood       Date:  2014-04-16       Impact factor: 22.113

9.  Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012.

Authors:  Michel Meignan; Sally Barrington; Emmanuel Itti; Andrea Gallamini; Corinne Haioun; Aaron Polliack
Journal:  Leuk Lymphoma       Date:  2013-06-14

10.  ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

Authors:  Massimo Federico; Stefano Luminari; Emilio Iannitto; Giuseppe Polimeno; Luigi Marcheselli; Antonella Montanini; Antonio La Sala; Francesco Merli; Caterina Stelitano; Samantha Pozzi; Renato Scalone; Nicola Di Renzo; Pellegrino Musto; Luca Baldini; Giulia Cervetti; Francesco Angrilli; Patrizio Mazza; Maura Brugiatelli; Paolo G Gobbi
Journal:  J Clin Oncol       Date:  2009-01-05       Impact factor: 44.544
View more
  4 in total

Review 1.  Optimal Therapy for Early-Stage Hodgkin's Lymphoma: Risk Adapting, Response Adapting, and Role of Radiotherapy.

Authors:  Andrea Riccardo Filippi; Mario Levis; Rahul Parikh; Bradford Hoppe
Journal:  Curr Oncol Rep       Date:  2017-05       Impact factor: 5.075

Review 2.  The GHSG Approach to Treating Hodgkin's Lymphoma.

Authors:  Paul J Bröckelmann; Andreas Engert
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

Review 3.  The Strategies to Homogenize PET/CT Metrics: The Case of Onco-Haematological Clinical Trials.

Authors:  Stephane Chauvie; Fabrizio Bergesio
Journal:  Biomedicines       Date:  2016-11-15

Review 4.  Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.

Authors:  Yucai Wang; Grzegorz S Nowakowski; Michael L Wang; Stephen M Ansell
Journal:  J Hematol Oncol       Date:  2018-04-23       Impact factor: 17.388
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.